Truist cuts Sangamo stock target to $5, maintains Buy rating
Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...
Truist Financial Keeps Their Buy Rating on Sangamo Biosciences (SGMO)
Truist Financial analyst Nicole Germino maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of ...
Sangamo Biosciences Holds Steady Amid Partnership Prospects and Program Uncertainties
Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of ...
Investing22d
H.C. Wainwright defends Sangamo shares after sell-off, reiterates Buy on pipeline confidence
On Thursday, H.C. Wainwright reaffirmed a positive stance on Sangamo BioSciences (NASDAQ:SGMO), maintaining a Buy rating and a $10.00 price target. Currently trading at $1.02 with a market ...
Nasdaq25d
Sangamo Biosciences Faces Pfizer Collaboration Termination
Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor ...
CNN1y
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited ...
technologynetworks1mon
Cell Culture – News and Features
Sangamo’s research collaboration with LifeScan illustrates the potential of Sangamo’s ZFP technology to play a key role in regenerative medicine approaches. Some of the products that Cellomics offers ...